CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase II Two-Arm Open-Label Study of Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT03724968
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:13.300520+00:00
- Published At
- 2021-03-05T00:00:00+00:00
- Record Updated At
- 2021-04-20
- Results Posted At
- 2021-03-05
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Metastatic Melanoma", "Advanced Melanoma", "Metastatic Melanoma Stratified by MHC-II Expression"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-04-20"- protocolSection.identificationModule.nctId
"NCT03724968"- protocolSection.identificationModule.officialTitle
"A Phase II Two-Arm Open-Label Study of Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression"- protocolSection.statusModule.overallStatus
"TERMINATED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2021-03-05"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.